Cholinergic therapy for Alzheimer's disease

Annals of Long-Term Care

Volumn 6, Issue 3, 1998, Pages 92-

  Levy, Morgan L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54649085094     PISSN: 15247929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C. The cholinergic hypothesis: A historical overview, current perspective, and future directions. Ann NY Acad Sci 1985;444:332-358.
2. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996;47:876-883.
3. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
4. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
5. Nieuwenhuys R. Chemoarchitecture of the Brain. New York: Springer-Verlag; 1985.
6. Davies P. Studies on the neurochemistry of central cholinergic systems in Alzheimer's disease. In: Katzman TR, Bick KL, ed. Alzheimer's Disease: Senile Dementia and Related Disorders. New York: Raven Press; 1978:453-459.
7. Procter AW, Lowe SL, Palmer AM, et al. Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 1988;84:125-140.
8. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
9. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
10. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a U.S. multicentre, randomized, double-blind, placebo-controlled trial: The Donepezil Study Group. Dementia 1996;7:293-303.
11. Kim YS, Nibbelink DW, Overall JE. Factor structure and reliability of the Alzheimer's disease assessment scale in a multicenter trial with linopirdine. J Geriatr Psychiatry Neurol 1994;7:74-83.
12. Talwalker S, Overall JE, Srirama MK, Gracon SI. Cardinal features of cognitive dysfunction in Alzheimer's disease: A factor-analytic study of the Alzheimer's disease assessment scale. J Geriatr Psychiatry Neurol 1996;9:39-46.
13. Olin JT, Schneider LS. Assessing response to tacrine using the factor analytic structure of the Alzheimer's disease assessment scale (ADAS)-cognitive subscale. Int J Geriatr Psychiatry 1995;10:753-756.
14. Miller E. On the nature of the memory disorder in presenile dementia. Neuropsychology 1971;9:75-81.
15. Miller E. Efficiency of coding and the short term memory defect in presenile dementia. Neuropsychology 1972;10:133-136.
16. Cummings JL, Trimble MR. Neuropsychiatry and Behavioral Neurology. Washington, DC: American Psychiatric Press Inc; 1995.
17. Cummings JL, Benson F, Hill MA, Read S. Aphasia in dementia of the Alzheimer type. Neurology 1985;35:394-397.
18. Rapcsak SZ, Croswell CS, Rubens AB. Apraxia in Alzheimer's disease. Neurology 1989;39:664-668.
19. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135.
20. Levy ML, Fairbanks LA, Masterman D, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci. In press.
21. Craig AH, Cummings JL, Fairbanks L, et al. Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996;53:1116-1120.
22. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
23. Kotrla KJ, Chacko RC, Harper RG, et al. SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry 1995;152:1470-1475.
24. Mentis MJ, Weinstein EA, Horwitz B, et al. Abnormal brain glucose metabolism in the delusional misidentification syndromes: A positron emission tomography study in Alzheimer disease. Biol Psychiatry 1995;38:438-449.
25. Ponton MO, Darcourt J, Miller BL, et al. Psychometric and SPECT studies in Alzheimer's disease with and without delusions. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1995;8:264-270.
26. Starkstein SE, Vazquez S, Petracca G, et al. A SPECT study of delusions in Alzheimer's disease. Neurology 1994;44:2055-2059.
27. Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995;7:476-484.
28. Levy ML , Fairbanks LA, Bravi D, et al. Cognitive predictors of emergent psychosis in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. In press.
29. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993;33:536-541.
30. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-473.
31. Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: A dose-response study. Arch Gen Psychiatry 1987;44:418-426.
32. Gorman DG, Read S, Cummings JL. Cholinergic therapy of behavioral disturbance in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1993;6:229-234.
33. Weiner MF, Edland SD, Luszczynska H. Prevalence and incidence of major depression in Alzheimer's disease. Am J Psychiatry 1994;151:1006-1009.
34. Davis KL, Hollander E, Davidson M, et al. Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry 1987;144:468-471.
35. Whitehouse PJ. Intraventricular bethanechol in Alzheimer's disease: A continuing controversy [editorial]. Neurology 1988;38:307-308.
36. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality: Tacrine Study Group. Neurology 1996;47:166-177.
37. Ryden MB. Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord 1988;2:342-355.
38. Dura JR, Stukenberg KW, Kiecolt-Glaser JK. Anxiety and depressive disorders in adult children caring for demented parents. Psychol Aging 1991;6:467-473.
39. Pillemer K, Suitor JJ. Violence and violent feelings: What causes them among family caregivers? J Gerontol 1992;47(suppl):165-172.
40. Snow C. Medicare HMOs develop plan for future of Alzheimer's programming. Modern Healthcare 1996;26:66-68,70.
41. Gracon SI. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. Acta Neurol Scand Suppl 1996;165:114-122.
42. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271:992-998.